Scholars@Duke

Combination therapy with sorafenib and celecoxib for pediatric patients with desmoid tumor.

Publication ,  Journal Article
Robles, J; Keskinyan, VS; Thompson, M; Davis, JT; Mater, DV
Published in: Pediatr Hematol Oncol
August 2020
Published version (DOI) Link to item

Duke Scholars

David Sinclaire Van Mater
Author David Sinclaire Van Mater Pediatrics, Hematology-Oncology

Published In

Pediatr Hematol Oncol

DOI

10.1080/08880018.2020.1735591

EISSN

1521-0669

Publication Date

August 2020

Volume

37

Issue

5

Start / End Page

445 / 449

Location

England

Related Subject Headings

  • Treatment Outcome
  • Sorafenib
  • Risk Factors
  • Receptors, Platelet-Derived Growth Factor
  • Protein Kinase Inhibitors
  • Oncology & Carcinogenesis
  • Male
  • Magnetic Resonance Imaging
  • Humans
  • Fibromatosis, Aggressive
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Robles, J., Keskinyan, V. S., Thompson, M., Davis, J. T., & Mater, D. V. (2020). Combination therapy with sorafenib and celecoxib for pediatric patients with desmoid tumor. Pediatr Hematol Oncol, 37(5), 445–449. https://doi.org/10.1080/08880018.2020.1735591
Robles, Joanna, Vahakn S. Keskinyan, Matthew Thompson, Joseph T. Davis, and David Van Mater. “Combination therapy with sorafenib and celecoxib for pediatric patients with desmoid tumor.” Pediatr Hematol Oncol 37, no. 5 (August 2020): 445–49. https://doi.org/10.1080/08880018.2020.1735591.
Robles J, Keskinyan VS, Thompson M, Davis JT, Mater DV. Combination therapy with sorafenib and celecoxib for pediatric patients with desmoid tumor. Pediatr Hematol Oncol. 2020 Aug;37(5):445–9.
Robles, Joanna, et al. “Combination therapy with sorafenib and celecoxib for pediatric patients with desmoid tumor.” Pediatr Hematol Oncol, vol. 37, no. 5, Aug. 2020, pp. 445–49. Pubmed, doi:10.1080/08880018.2020.1735591.
Robles J, Keskinyan VS, Thompson M, Davis JT, Mater DV. Combination therapy with sorafenib and celecoxib for pediatric patients with desmoid tumor. Pediatr Hematol Oncol. 2020 Aug;37(5):445–449.

Published In

Pediatr Hematol Oncol

DOI

10.1080/08880018.2020.1735591

EISSN

1521-0669

Publication Date

August 2020

Volume

37

Issue

5

Start / End Page

445 / 449

Location

England

Related Subject Headings

  • Treatment Outcome
  • Sorafenib
  • Risk Factors
  • Receptors, Platelet-Derived Growth Factor
  • Protein Kinase Inhibitors
  • Oncology & Carcinogenesis
  • Male
  • Magnetic Resonance Imaging
  • Humans
  • Fibromatosis, Aggressive